Shashank Cingam
Hematology & Oncology · Shreveport, LANPI 1639552870
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Janssen Scientific Affairs, LLC at 44.0% of the total. Reporting peaked in 2024 at $3,338 and has fallen 69.7% since, to $1,011 in 2025.
Across 47 payments — averaging $146.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$3K
- AbbVie$2K
- Incyte Corporation$270
- Bristol Myers Squibb$237
- Karyopharm Therapeutics Inc.$234
- Pharmacyclics LLC, An Abbvie Company$228
- plus $915 from 18 others
Across 24 payments — averaging $11,002 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$240K
- E.r. Squibb & Sons, L.L.C.$24K
What the payments were for
- Consulting fees$3,02544%
- Travel & lodging$1,70225%
- Food & beverage$2,14131%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 2 | $3,025 |
| AbbVie | 9 | $1,959 |
| Incyte Corporation | 3 | $270 |
| Bristol Myers Squibb | 5 | $237 |
| Karyopharm Therapeutics Inc. | 2 | $234 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $228 |
| Pfizer | 2 | $152 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Sanofi-aventis U.S. LLC | 1 | $125 |
| Novartis | 1 | $112 |
| AstraZeneca(2 entities) | 2 | $52 |
| Regeneron Healthcare Solutions, Inc. | 2 | $49 |
| Genentech USA, Inc. | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Beone Medicines USA, Inc. | 2 | $35 |
| Daiichi Sankyo Inc. | 1 | $30 |
| Adaptive Biotechnologies Corporation | 1 | $24 |
| GSK | 1 | $24 |
| Astellas Pharma US Inc | 1 | $24 |
| Sanofi | 1 | $20 |
| Apellis Pharmaceuticals, Inc. | 1 | $20 |
| Legend Biotech USA Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $15 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,868 in reported general payments places this provider in the 60th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 23 | $337,691 |
| RevlimidLenalidomide | 14 | $289,514 |
| Acyclovir | 37 | $371 |
| Dexamethasone | 16 | $363 |
| Gabapentin | 16 | $123 |
| Ondansetron Hcl | 13 | $60 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $45 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $237 | $289,51414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 183 hematology & oncology providers in Louisiana.
Other hematology & oncology in Shreveport
- Prakash PeddiShreveport$405K
- Kevin GallagherShreveport$145K
- Maxwell McDonaldShreveport$123K
- Kirtan KotichaShreveport$45K
- Tharwat GhattasShreveport$25K
- Joyce FeaginShreveport$19K
- Richard MansourShreveport$16K
- Kavitha BeedupalliShreveport$15K
- Steven BoniolShreveport$14K
- Gary BurtonShreveport$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.